The United Kingdom and the United States have finalized a major commercial pact that will preserve no import taxes on UK medicine exports going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to increase funding on medicines through the National Health Service (NHS). This commitment secures that tariffs on these key products will stay at nothing for a timeframe of the next three years.
This development comes after earlier warnings to dramatically increase duties on branded drug products, with figures floated as high as double the cost.
"This agreement with the Britain strengthens the worldwide climate for new treatments and brings much-needed equity to transatlantic medicine commerce," a statement said.
Commercial Impact
Drugs are one of the UK's largest export categories to the America, which is clearly the largest destination for leading UK drugmakers.
Trade data show that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This figure accounted for 17.4% of total UK exports in that span.
"This guarantee protects employment, stimulates capital expenditure and facilitates the UK to become a global hub for medical research," a minister remarked.
Key British Pledges
The pact entails several notable changes from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it deems new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates exceeded 20%.
Recent Tensions
The pact comes amid a protracted row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that US patients were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been paused or abandoned, while substantial investments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on treatments, noting that its expenditure on drugs had declined as a proportion of its overall budget over the past decade.
